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TP53 is one of the most frequently inactivated tumor suppressor genes in human cancer. 
However, unlike other tumor suppressor genes whose expression is lost, TP53 is usually 
inactivated as a result of a single nucleotide change within the coding region. Typically, 
these single nucleotide mutations result in a codon change that creates an amino acid 
substitution. Thus, unlike other tumor suppressor genes whose expression is lost due 
to genetic or epigenetic changes, the p53 gene primarily suffers missense mutations, 
and therefore, the cells retain and express a mutant form of the p53 protein (mtp53). It 
is now well established that mtp53 contributes to tumor development through its gain-
of-function (GOF) activities. These GOF activities can arise from novel protein–protein 
interactions that can either disable other tumor suppressors (e.g., p63 and p73) or 
enable oncogenes such as ETS2, an ETS family member. In this review, I will focus on 
the identification of the mtp53/ETS2 complex and outline the diverse activities that this 
transcriptional regulatory complex controls to promote cancer.
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SiMULTAneOUS inACTivATiOn OF wiLD-TYPe p53’s TUMOR 
SUPPReSSOR ACTiviTY AnD ACTivATiOn OF MUTAnT p53’s 
GOF ACTiviTieS
The majority of mutations in the p53 gene cluster within the region that encodes the DNA-binding 
domain. Some of these mutations alter the overall conformation of the protein (referred to as 
structural mutants), while other mutations do not alter the structure but instead change an amino 
acid that is critical for DNA binding (referred to as DNA contact mutants) (1, 2). These muta-
tions typically give rise to mtp53 proteins that have lost the capacity to bind to the wild-type p53 
(WTp53) consensus binding site and are thus unable to associate with WTp53 response elements in 
the genome and therefore unable to regulate WTp53 target genes. However, mtp53 is present on the 
promoters of various genes and is able to regulate their expression (1, 2). These observations indicate 
that despite having lost its WTp53 sequence-specific DNA-binding activity, mtp53 is still capable of 
acting like a transcription factor.
Initial studies on mtp53 relied on the overexpression of its cDNA in cells that were p53 null (3). 
In these studies, it was shown that mtp53 functions in a manner that is diametrically opposed to the 
tumor suppressor functions of WTp53. Instead of suppressing cancer or simply acting like an inert 
protein (due to its mutational inactivation), the mtp53 protein exhibited GOF activities, which allowed 
it to promote growth and tumorigenesis (3). From these studies, it became apparent that mtp53 can 
function as an oncogene, and these GOF activities were most apparent when the mtp53 harboring 
cells were challenged, for example, with proapoptotic stimuli (1, 2). The advent of siRNA technology 
permitted endogenous mtp53 to be suppressed in cells, which resulted in apoptosis (4). These data 
argued that mtp53 is actively engaged in promoting cell survival, and thus, cells harboring these 
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mutant proteins exhibit an addiction to them. Addiction to mtp53 
has since been demonstrated by various groups and has recently 
been genetically confirmed in mice (5, 6). It is important to note 
from these latter studies in  vivo that early intervention delays 
the tumorigenesis process, which could indicate that mtp53 is 
required to drive the carcinogenic pathway early on and possibly 
that addiction to this oncogene is an early occurring event, even 
in cells that are not yet “transformed.” This latter view is supported 
by the fact that siRNA knockdown of mtp53 in non-transformed/
non-tumorigenic Li–Fraumeni fibroblasts resulted in apoptosis, 
indicating that these cells exhibited oncogene addiction (4).
MeCHAniSTiC BASiS FOR MUTAnT p53’s 
TRAnSCRiPTiOnAL ReGULATORY 
OnCOGeniC FUnCTiOnS
To investigate the basis of its GOF activities, we and others have 
performed genome-wide analysis of mtp53 binding, and through 
bioinformatics and biochemical analysis have determined that 
mtp53 can be recruited to promoters via interactions with other 
transcription factors (7–11). Many of these transcription factors 
that bind to mtp53 have also been shown to interact with WTp53 
(E2F1, NF-Y, VDR, ETS1, ETS2, and SP1), although there are 
some discrepancies among different studies (7–12). For example, 
one of the earliest studies to show that mtp53 regulates gene 
expression via the recruitment mechanism was on the regulation 
of the MDR1 promoter (13). In this study, it was reported that 
ETS1 can only interact with mtp53 and not with WTp53 (13). 
Other studies had shown that WTp53 can also interact with ETS1 
(14, 15). ETS1 has been shown to be required for the transcrip-
tional regulatory activity of WTp53 (16). Thus, it appears that 
both the oncogenic and tumor suppressor forms of p53 might rely 
on the ETS factors. We and others have reported that WTp53 at 
best poorly interacts with ETS1 (10, 11). What is the basis for the 
discrepancies between studies? It is possible that there might be 
tissue-specific or stress-dependent conditions that permit WTp53 
to interact with ETS family members, although some studies 
were conducted in vitro. Additionally, WTp53 has been shown to 
undergo conformational changes during cell cycle progression. 
In this case, the protein can adapt mtp53-like conformational 
attributes (17–20). Does this reflect a conformational speciation 
of p53, where depending on cellular growth conditions or stress, 
p53 can adapt to different conformations that transiently increase 
its binding partners’ repertoire. If this is the case, perhaps WTp53 
can oscillate between different conformational species, a “minor” 
form of which is able to interact with ETS1. In contrast, mtp53 
is locked in the minor form conformation that allows it to bind 
extensively to other protein partners including ETS1.
THe e26 TRAnSFORMATiOn-SPeCiFiC 
MOTiF iS OveRRePReSenTeD in 
MUTAnT p53 OCCUPieD PROMOTeRS
Chip-Chip and Chip-Seq data revealed that approximately 50% 
of the promoters occupied by mtp53 contain ETS-binding sites, 
suggesting that the association with ETS proteins is a prominent 
mechanism by which mtp53 regulates gene expression (10, 11). 
Mtp53 has been shown to associate with promoter regions of 
genes in an ETS2-dependent manner (10, 11). Importantly, these 
mtp53-bound genomic regions do not have a WTp53 response 
element, indicating that the mtp53 protein is not associating with 
these targets through residual activity of its DNA-binding domain 
(10, 11). Additionally, these mtp53 target genes do not overlap 
with WTp53 target genes that are identified through a similar 
genome-wide analysis, further demonstrating that mtp53 associ-
ates with these promoters in a completely novel manner (10, 11). 
Although the interaction with ETS1 might be important for the 
regulation of some mtp53 target genes, side-by-side comparison 
using recombinant proteins revealed that mtp53 preferentially 
associates with ETS2, another ETS family member (10). Both the 
structural and DNA contact p53 mutants interacted with ETS1, 
albeit with seemingly less affinity (10). It was also noted that the 
structural mutant (R175H) bound ETS1 better than the DNA 
contact (R248W) mutant. Importantly, all structural and DNA 
contact p53 mutants that have been tested thus far interact with 
ETS2 (10, 11). Moreover, whereas ETS1 knockdown generally 
has no effect on mtp53 target gene expression, ETS2 knockdown 
recapitulates the changes in gene expression that occur upon 
mtp53 knockdown (10, 11, 21, 22). Nevertheless, the observation 
that ETS2 interacts with various mtp53 (R175H, R248Q, R248W, 
R249S, R273H, R273L, and R280K) suggests that by coupling 
with ETS2, different mtp53 proteins are able to exert oncogenic 
activities through a common platform. The mtp53 proteins 
that have been tested correspond to the “hot-spot” mutations. 
It will be of interest to determine if proteins generated by mis-
sense mutations that are outside the region encompassed by the 
cluster of hot-spot mutations also interact with ETS2. However, 
further analysis is required to determine if all cancer-associated 
p53 mutants interact with ETS2. This is an important analysis 
because it has long been established that there are differences in 
the oncogenic potency of distinct p53 mutants, which might be 
related to their affinity for ETS2 or even other ETS factors. In this 
regard, it will be important to determine if p53 mutants that are 
more active than WTp53 in transcriptional and cell killing assays 
also interact with ETS2 (23).
It is of particular interest to note that ETS2 binds to the 
tetramerization domain of p53, which is thought to be func-
tionally intact in both WTp53 and mtp53 (10). The question of 
how ETS2 distinguishes between mtp53 and WTp53 is further 
highlighted by the fact that some p53 mutants are considered 
to have subtle changes in their structure but are otherwise 
conformationally similar to WTp53. Intriguingly, it has been 
suggested that because WTp53 is actively engaged in sampling 
DNA sequences throughout the genome, it might not be able to 
interact with ETS2 (24). A corollary of this model would be that 
when WTp53 is associated with DNA, it might alter its structure 
in a manner that is incompatible with binding to ETS2. However, 
both overexpression and in  vitro studies using recombinant 
proteins failed to show a strong interaction between WTp53 and 
ETS2. In the overexpression experiments, it seems unlikely that 
all of the transfected WTp53 protein is bound to DNA and thus 
cannot bind ETS2. Furthermore, the observation that the WTp53 
FiGURe 2 | Mutant p53 disrupts eTS family target gene regulation. The 
ETS family of transcription factors share multiple target genes based on their 
ability to bind a common DNA motif. These shared targets can be regulated 
in a cooperative or opposing manner in order to maintain homeostatic control 
of gene expression. The presence of mtp53 causes ETS2 to accumulate and 
outcompete other ETS family members for binding to target genes, 
potentially altering their repression/activation by recruiting co-repressors 
(Co-R) or co-activators (Co-A).
FiGURe 1 | Mutant p53 protects eTS2 from degradation. ETS2 is a 
labile protein with a short half-life. An E3-ubiquitin ligase binds to ETS2 and 
promotes its ubiquitin-dependent degradation. In the presence of mtp53, 
ETS2 is not ubiquitinated and becomes stable, which increases its 
abundance allowing it to recruit mtp53 to ETS target genes.
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and ETS2 purified proteins do not interact in vitro casts doubt 
on, yet does not eliminate, the possibility that the structural 
changes due to DNA binding by WTp53 prevent its interaction 
with ETS2 (10).
DOMAin ReQUiReMenTS FOR MUTAnT 
p53’s TRAnSCRiPTiOnALLY 
DePenDenT GOF
Since WTp53 has potent transactivation domains in its 
N-terminus, this raises the possibility that mtp53 can also utilize 
them to regulate gene expression. In support of this, mutation 
of the N-terminal transactivation domain of mtp53 eliminated 
its ability to activate the MDR-1 promoter and enhances tumori-
genic potential (25). A similar conclusion was drawn in another 
study, in which the N-terminus was shown to be required for the 
transactivation activity of mtp53 (26). In contrast, it was observed 
that the C-terminus was required for mtp53 to promote tumori-
genicity (26). Likewise, an intact transactivation domain appears 
to be required for mtp53 to promote chemotherapy resistance 
(27, 28). It appears that mtp53 may be able to mediate GOF 
activities using different domains. The precise mechanism(s) by 
which these mutations disable its oncogenic activity is not well 
understood; however, it has been reported that mutation of the 
transactivation domain in mtp53 disrupts its interaction with 
ETS1 (13).
An mtp53, in which the transactivation domain was mutated, 
was still capable of activating the promoter of one of its target 
genes, TDP2, in a luciferase assay (10). An mtp53 mutant lacking 
the C-terminus, which eliminates the interaction with ETS2, was 
unable to activate this promoter (10). However, p53 contains two 
transactivation domains, and mutation of both domains prevents 
mtp53 from disrupting mammary tissue architecture in vitro (29). 
These observations suggest that both transactivation domains 
may be required for mtp53 to exert its GOF. However, in the lat-
ter case, mtp53 was mediating its effects through an interaction 
with SREBP transcription factor, which raises the possibility that 
the domains required for GOF are dependent on the particular 
binding partner for mtp53.
MUTAnT p53 TAKeS CARe OF iTS 
PARTneR
If the transcriptional activation domain of mtp53 is not required 
for activation of gene expression, what is mtp53 contributing to 
this transcriptional regulatory complex? Importantly, mtp53 
can protect ETS2 from ubiquitin-dependent degradation, 
which raises the possibility that by increasing ETS2 abundance, 
mtp53 disrupts the balance between activator/repressor ETS 
family members, favoring the presence of mtp53/ETS2 on pro-
moter targets (Figures 1 and 2) (10, 30). Among the different 
mtp53 interacting proteins, ETS2 appears to be unique in that 
mtp53 protects it from degradation. There are various different 
proteins currently implicated in promoting ETS2 degradation 
including Cdh1/Fzr1, the adaptor protein for the APC/cyclo-
some complex; Cul4a, a subunit of the SCF ubiquitin ligase 
complex; the E3-ubiquitin ligase, COP1/RFWD2; and CDK10 
(31–34). Further work is required to establish how mtp53 
interferes with the function of one or all of these proteins to 
stabilize ETS2.
MUTAnT p53’s PARTneRinG wiTH eTS2 
COnFeRS iT ACCeSS TO A MULTiTUDe OF 
OnCOGeniC AnD TUMOR SUPPReSSive 
TRAnSCRiPTiOnAL TARGeTS
The ETS family of winged helix-turn-helix transcription factors 
consists of 28 family members that share a highly conserved 
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DNA-binding domain, referred to as the ETS domain (30). 
The ETS domain permits all the family members to bind in a 
sequence-specific manner to a common core motif, GGAA 
[called the ETS-binding site (EBS)], and thus, they share many 
transcriptional targets (30). This overlapping set of targets raises 
the question of why there is such redundancy in gene regulation. 
The perplexing redundancy in gene targets is explained by the 
fact that ETS family members largely exhibit tissue-specific 
expression and that they can play both cooperative and/or 
opposing roles in regulating gene expression (30, 35). As such, 
only a subset of ETS family members are expressed in a given 
tissue, and the particular ETS family member that is occupying 
a particular binding site is dependent on extracellular cues (36). 
Ectopic expression of oncogenic ETS proteins can functionally 
substitute for activation of the Ras/MAPK pathway, implying that 
control of oncogenic ETS factor levels is imperative to prevent 
neoplastic transformation (37). The ETS family regulates diverse 
cellular activities including apoptosis, angiogenesis, cell growth, 
adhesion, migration/invasion, the extracellular matrix, and other 
transcription factors (30). Thus, by interacting with ETS2, mtp53 
can hijack the ETS transcriptional repertoire and control many of 
these processes to promote cancer.
As can be surmised from the various cellular activities that 
the ETS family controls, the ETS family members can function as 
either oncogenes or tumor suppressor genes, and sometimes the 
context determines their role in promoting or suppressing cancer. 
For example, ELF3 is frequently mutated in cervical, mucinous 
ovarian, and biliary tract cancers (38–40). Ectopic expression 
of wild-type ELF3 suppresses cell growth of biliary tract and 
cervical cancer cells suggesting a tumor suppressor role in these 
cancers (38, 39). In contrast, ELF3 has been shown to function as 
an oncogene in colorectal and prostate cancer (41, 42). SPDEF, a 
prostate epithelium-specific ETS transcription factor, suppresses 
prostate cancer progression and metastasis (43–45). Knockdown 
of another ETS family member, ESE3/EHF, in normal prostate cells 
resulted in the acquisition of mesenchymal and stem-like charac-
teristics (46). Chromosomal rearrangements have been shown 
to give rise to oncogenic gene fusions for multiple ETS family 
members including ERG, ETV1, ETV4, ETV5, ETV6, ELK4, and 
FLI1 (47). Importantly, ETS2 itself has been shown to be deleted in 
a subset of prostate cancers and to have a growth inhibitory func-
tion, suggesting that it is a tumor suppressor gene in this tissue. In 
addition, a transgenic mouse overexpressing ETS2 in the thymus 
had increased p53-dependent apoptosis (48). Previously, it has 
been shown that Ets2 dosage can impact tumor development in 
the APCMin mouse model (49). Mice carrying extra copies of ETS2 
were protected from tumor development, whereas ETS2 heterozy-
gous mice exhibited higher cancer frequency (49). It is interesting 
to note that in the context of mutant p53 harboring cells, ETS2 
abundance is increased yet it appears to function as an oncogene. 
Given that ETS2 has been shown to activate p53-dependent 
apoptosis, it is possible that the loss of wild-type p53 provides a 
permissive environment for ETS2 to have oncogenic functions. 
Taken together, the ability of mutant p53 to stabilize ETS2 and to 
utilize it to regulate gene expression constitutes a novel mechanism 
by which an ETS family member promotes cancer.
ALTeReD TARGeT SeLeCTiOn vS. 
AMPLiFieD ReGULATiOn
There are various aspects of the mtp53/ETS2 regulatory complex 
that remain to be explored. For example, are the genes regulated 
by mtp53/ETS2 different from the ones regulated by ETS2 
alone? Additionally, does the mtp53/ETS2 interaction alter the 
regulation (i.e., activation or repression) of these target genes? 
Since ETS2 is induced by growth factor receptor pathways, does 
mtp53 unlink it from mitogenic signaling and thereby produce 
a constitutively active ETS2. A clue comes from the observation 
that many of the mtp53/ETS2 target genes are controlled by ETS2 
in cells lacking p53 (21, 22). This suggests that mtp53 is not alter-
ing the spectrum of genes that ETS2 controls but rather further 
enhancing their expression. For example, mtp53 was shown to 
upregulate nucleotide metabolism genes (NMG) expression by 
associating with their promoters, and suppression of mtp53 
or ETS2 reduced their expression (22). In cells lacking mtp53 
(i.e., either containing WTp53 or lacking p53 altogether), ETS2 
knockdown reduced the expression of these target genes (22). 
Introduction of mtp53 increased ETS2 protein and NMG expres-
sion to levels higher than in cells lacking mtp53 (22). These data 
reinforce the notion that the mtp53/ETS2 complex upregulates 
NMG expression. Again, in this situation, ETS2 knockdown in 
cells ectopically expressing mtp53 reduced NMG expression, 
despite the fact that it did not affect mtp53 levels (22). These 
data suggest that the mtp53-mediated aberrant accumulation 
of ETS2 can enhance the expression of ETS2 target genes. In 
addition, removal of mitogens (via serum deprivation) results 
in reduced expression of the NMG in cells lacking mtp53, yet 
has no effect in cells expressing mtp53 (22). This observation 
raises the possibility that mtp53 is capable of superseding the 
mitogenic control of ETS2 function. Whether mtp53 is obviating 
intrinsic ETS2 auto-inhibitory activity or simply increasing its 
abundance, or both, to enhance ETS2 function requires further 
investigation (50).
FUTURe DiReCTiOnS
The cooperation between mtp53 and ETS2 to regulate gene 
expression is well established in  vitro, but the extent to which 
these two work together to promote tumorigenesis in vivo is still 
not known. Furthermore, there is circumstantial evidence that 
mtp53’s GOF depends on several domains, and thus, it will be 
important to dissect these different domains in vivo to determine 
if one of these is dominant or whether the GOF is mediated by 
the action of multiple domains in mtp53.
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